| Revenue growth | 6.9% YoY for FY26; non-GPL business grew 13%. |
|---|---|
| Margins | Record 33.6% FY26 EBITDA margin, up 360bps YoY. |
| Order book | Closing 2 new CDMO deals expected in H2 FY27. |
| Demand visibility | Pretty good across regulated markets and CDMO segment. |
| Management confidence | High; confident in sustaining 30-32% margins despite headwinds. |
Growth
FY26 revenue grew 6.9% to ₹2,552cr; PAT stood at ₹565cr with 22.1% margins; EBITDA up 19.6% YoY.
Outlook
Guided 30-32% EBITDA margins; ₹540cr FY27 capex plan; Solapur Phase 1 operational by Q2 FY27.
Risks
Geopolitical conflicts impacting supply chains, elevated logistics/energy costs, and raw material price inflation (solvents).
Earnings Call filed with BSE, NSE: ALIVUS. Summary written with AI assistance from the document.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,380.00
- Market cap
- ₹16,942 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 28.1×Sector 47.4×
- Promoter holding
- 74.87%+0.00% QoQ
- FII holding
- 5.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Merger & Restructuring Worth ₹0.9 Cr
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
- Value
- ₹0.90 Cr
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus Life Sciences Merger & Restructuring Worth ₹9.12 Cr
Alivus Life Sciences Limited will acquire a 76% stake in IQGEN-X Pharma Private Limited for approximately ₹9.12 Crore. This strategic acquisition enhances the company's CDMO solution offerings.
- Value
- ₹9.12 Cr
Alivus Life Sciences Business Update
Alivus Life Sciences submitted its Business Responsibility & Sustainability Report for FY 2025-26, detailing operational metrics, employee statistics, and sustainability performance.
Alivus Life Sciences Annual Report
Alivus Life Sciences Limited has filed its Integrated Annual Report for FY 2025-26 in compliance with Regulation 34(1) of SEBI Listing Regulations.
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences will hold its 15th AGM on September 8, 2026. The company fixed September 1, 2026, as the record date for a Rs. 5.00 dividend.